Fate Therapeutics Q2 FY26 net loss narrows to $30.2 million; revenue rises to $2.1 million
Reuters2026/08/13 12:33- Fate Therapeutics posted Q2 2026 net loss of USD 30.2 million, or USD 0.25 per share, narrowing from USD 34.1 million.
- Revenue rose to USD 2.1 million from USD 1.9 million, driven by preclinical work under the Ono Pharmaceutical collaboration.
- Total operating expenses fell to USD 33.2 million from USD 38.9 million, including USD 24.4 million in RD.
- Cash, cash equivalents, and investments ended June 30 at USD 153.8 million, down USD 21 million on the quarter.
- First patient was dosed in RECLAIM-LN for FT819; FDA cleared the FT839 IND, with cash runway expected into 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
Crypto prices
More
